Spongistatins as Tubulin Targeting Agents

Authors: Uckun, F.M.; Mao, C.; jan, S.; Huang, H.; Vassilev, A.O.; Navara, C.S.; Narla, R.K.

Source: Current Drug Metabolism, Volume 7, Number 13, 1 September 2001 , pp. 1291-1296(6)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Recently identified novel agents that disrupt tubulin polymerization include synthetic spiroketal pyrans (SPIKET) targeting the spongistatin binding site of beta tubulin. These agents exhibit anticancer activity by disrupting normal mitotic spindle assembly and cell division as well as inducing apoptosis. At nanomolar concentrations, the SPIKET compound SPIKET-P caused tubulin depolymerization in cell-free turbidity assays and exhibited potent cytotoxic activity against cancer cells as evidenced by destruction of microtubule organization, and prevention of mitotic spindle formation in human breast cancer cells. SPIKET compounds represent a new class of tubulin targeting agents that show promise as anti-cancer drugs.

Keywords: Spongistatins; Tubulin Targeting Agents; spiroketal pyrans (SPIKET); anticancer activity; SPIKET; SPIKET-P; anti-cancer drugs; Spiroketal Pyrans (SPIKET-P); Beta Tubulin; colchicine

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612013397492

Publication date: 2001-09-01

More about this publication?

Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.